# Heavy Chains, Heavy Consequences: A Case of Concomitant Heavy Chain Amyloidosis and Heavy Chain Deposition Disease

**Authors:** Bismark Kojo Amoh, Ghadi Ghanem, Jonathan E. Zuckerman, Zachary Bruss, Kelley Chuang

PMC · DOI: 10.1016/j.xkme.2025.101102 · Kidney Medicine · 2025-09-12

## TL;DR

This paper reports a rare case of two kidney-related diseases caused by abnormal antibody proteins in an elderly man.

## Contribution

The study presents a unique case of combined IgG4-type heavy chain amyloidosis and heavy chain deposition disease.

## Key findings

- The patient had both heavy chain amyloidosis and heavy chain deposition disease, a rarely reported combination.
- The patient's condition improved with hemodialysis and chemotherapy.
- The case highlights diagnostic and management challenges of this rare disease combination.

## Abstract

Heavy chain (AH) amyloidosis is a rare form of primary systemic amyloidosis that predominantly affects the kidneys and can lead to nephrotic syndrome. It is marked by the deposition of amyloid fibrils derived from immunoglobulin (Ig)-heavy chains. Monoclonal immunoglobulin deposition disease is a similarly rare disorder involving deposition of nonfibrillar and Congo red-negative monotypic Ig molecules in basement membranes. It can be derived from Ig light chains, Ig heavy chains, or Ig light and heavy chains. Cases of combined amyloidosis and monoclonal immunoglobulin deposition disease are exceedingly rare. Only a handful of concomitant amyloidosis and heavy chain deposition disease have been previously reported, and the spectrum of such diagnoses is poorly described. We describe a case of concomitant IgG4-type AH amyloidosis and heavy chain deposition disease in an 83-year-old man with a history of Agent Orange exposure who developed nephrotic syndrome resulting in diuretic-resistant anasarca. A subsequent bone marrow biopsy demonstrated a λ-restricted plasma cell population. The patient was initiated on hemodialysis and chemotherapy, resulting in clinical stabilization. This case report also contrasts AH amyloidosis with other forms of amyloidosis, emphasizing its unique clinical features, diagnostic challenges, and management considerations.

## Linked entities

- **Diseases:** nephrotic syndrome (MONDO:0005377), amyloidosis (MONDO:0019065), heavy chain amyloidosis (MONDO:0018613), heavy chain deposition disease (MONDO:0019728)

## Full-text entities

- **Diseases:** nephrotic syndrome (MESH:D009404), anasarca (MESH:D004487), Heavy Chain Amyloidosis and (MESH:D006362), primary systemic amyloidosis (MESH:D000075363), AH (MESH:D007039), Monoclonal immunoglobulin deposition disease (MESH:D000079822), amyloidosis (MESH:D000686)
- **Chemicals:** Chains (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12593563/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12593563/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12593563/full.md

---
Source: https://tomesphere.com/paper/PMC12593563